Introduction
============

Nasopharyngeal carcinoma (NPC), a squamous-cell carcinoma, is more prevalent in northern Africa, Alaska, Southeast Asia, and in particular, in the Guangdong area localized at southern part of People's Republic of China,[@b1-ott-8-3255] where its incidence is estimated as 80 cases per 100,000, which leads to great threat to the health of affected people.[@b2-ott-8-3255] Meanwhile, it is noteworthy that the incidence of NPC is higher among Chinese people immigrated to Southeast Asia or North America but is lower among those born in North America than born in southern part of People's Republic of China.[@b3-ott-8-3255] Obviously, there is an urgent need to improve treatment outcomes of NPC patients.

NPC is generally considered to be radio- and chemo-sensitive in patient care. Several randomized controlled trials (RCTs) have indicated that use of the radiation therapy in combination with chemotherapy synchronously or sequentially is efficient for NPC patients.[@b5-ott-8-3255],[@b6-ott-8-3255] Currently, concomitant use of radiotherapy and chemotherapy (or called concurrent chemoradiotherapy \[CCRT\]) is generally recognized as the standard of treatment for locally advanced NPC.[@b7-ott-8-3255] However, clinical observations have shown that \~30%--50% of NPC patients may have metastasis or relapse due to inability to achieve remission, suggesting that current therapy regimen can only control 50%--70% of locally advanced NPC cases successfully.[@b8-ott-8-3255],[@b9-ott-8-3255] Furthermore, RCTs have demonstrated that CCRT in combination with adjuvant chemotherapy provides a 31% increase in 3-year overall survival (OS) compared with CCRT alone.[@b10-ott-8-3255] The 2014 National Comprehensive Cancer Network (NCCN) guidelines recommended that CCRT followed by induction chemotherapy (IC) be acceptable for locally advanced NPC (T1N1-3/T2-4Nx).[@b11-ott-8-3255] Despite these advances, standard treatment regimens of IC have not been established as the first-line therapy because any of the following IC regimens could be chosen: docetaxel/cisplatin/fluorouracil, cisplatin/epirubicin/paclitaxel, and cisplatin/fluorouracil, the majority of which are taxane-containing regimens.

Taxane is a class of microtubule inhibitors, including paclitaxel and docetaxel (a taxol analog), which works by interfering with cell division. Some evidence has showed that tumor cells would have an increased sensitivity to radiotherapy when patients are treated with docetaxel.[@b12-ott-8-3255] Furthermore, a literature-based meta-analysis indicated the taxane-containing IC regimen (such as combined use of taxane, cisplatin, and fluorouracil) is superior to that not containing taxane (such as combined use of cisplatin and fluorouracil) with respect to progression-free survival and OS in patients with head and neck cancers recruited in randomized trials,[@b13-ott-8-3255] suggesting improved clinical outcomes by taxane. However, there were few discussions on taxane-containing IC regimen in NPC treatment, which compared clinical efficacy and safety of taxane-containing IC plus CCRT with those of non-taxane-containing IC plus CCRT in locally advanced NPC.[@b14-ott-8-3255]--[@b25-ott-8-3255] Here, we aimed to give an overview of all the eligible RCTs for estimated effects of paclitaxel or docetaxel, and to further establish the role of taxane in the standard of IC regimens for locally advanced NPC.

Materials and methods
=====================

Study design
------------

To elucidate the inclusion criteria, a protocol was written before literature search. The eligible trials had to meet the following inclusion criteria: the trials should be RCTs, and patients with locally advanced NPC (stage III--IV) should be treated with CCRT in combination with taxane-containing IC or non-taxane-containing IC, without any interference with other treatments. Retrospective studies and prospective studies were used in this meta-analysis.

Literature search
-----------------

Electronic databases, such as PubMed, Embase, MEDLINE, and Chinese Biomedical Database, were searched for eligible studies. The search terms included the following keywords: (\[nasopharyngeal carcinoma OR nasopharyngeal cancer OR cancer of nasopharynx OR NPC OR NPCa OR nasopharyngeal neoplasms\] AND \[paclitaxel OR docetaxel OR taxanes OR taxane OR aisui OR dopafei OR taxotere OR taxol\] AND \[RCTs OR randomized controlled trial\]). The language of literature was limited to English and Chinese. In addition, we used the PubMed option "Related Articles" in each paper to retrieve potentially relevant ones, and manually searched the references of all the included articles.

Data extraction
---------------

Two researchers independently performed data extraction (R Tian and BG Zhang) using a standard extraction form. To resolve discrepancies, group consensus and consulting with a third researcher were used (DY Gu). If the eligibility of the abstract was unclear, the full article was retrieved for clarification. Any problems were solved by discussion.

The deadline for trial inclusion was October 14, 2014.

Statistical analysis
--------------------

The primary clinical end point was OS, defined as the time from start of randomization until death from any cause. The secondary end points were overall response rate (ORR) and adverse drug reactions.

We used odds ratios (ORs) and 95% confidence intervals (CIs) to evaluate the strength of the associations. Short-term efficacy, 1-year survival rate, and different types of adverse events were compared with ORs and 95% CIs using *χ*^2^ test. Both the Cochran's *Q* statistic (testing for heterogeneity) and *I*^2^ statistic (quantifying the proportion of the total variations due to heterogeneity) were used to estimate heterogeneity across all individual studies included in this meta-analysis.[@b26-ott-8-3255],[@b27-ott-8-3255] If a *P*-value of the *Q* test was \<0.05, indicating a lack of heterogeneity across studies, the summary OR estimate of each study was calculated by the fixed-effects model (the Mantel--Haenszel method);[@b28-ott-8-3255] otherwise, random-effects model (the DerSimonian and Laird method) was used. STATA Version 10.0 was used for statistical analysis. All reported *P*-values were two-sided.[@b29-ott-8-3255]

Results
=======

Description of included studies
-------------------------------

Clinical characteristics of recruited NPC patients are summarized in [Table 1](#t1-ott-8-3255){ref-type="table"}. The eligible 12 RCTs included one study in English and eleven studies in Chinese, which have been published in the *Journals of Statistic Source*.[@b14-ott-8-3255]--[@b25-ott-8-3255] A total of 835 patients were enrolled. Among those, 412 (49.3%) received the taxane-containing IC regimens, and the rest received non-taxane-containing regimens in addition to CCRT. The sample size ranged from 21 to 76. All patients were diagnosed with advanced NPC (stage III--IV) histologically or pathologically. All studies were case--control studies, with records of complete remission (CR), partial release (PR), 1-year survival rates, and toxicities.

Short-term efficacy
-------------------

Clinical efficacy on primary nasopharyngeal lesion and metastatic lesions of cervical lymph nodes was evaluated for the taxane-containing regimen group and non-taxane-containing regimen group of NPC patients at 3 months after IC in combination with CCRT. As shown in [Table 2](#t2-ott-8-3255){ref-type="table"}, the pooled analysis of the short-term efficacy was performed, in which data on CR and PR of primary nasopharyngeal lesions were assessed in all 12 studies, and metastatic lesions of cervical lymph nodes were evaluated in eight of 12 studies. As shown in [Figure 1](#f1-ott-8-3255){ref-type="fig"}, taxane-containing IC regimen had a significantly increased ORR for nasopharyngeal lesion (OR =4.57, 95% CI =1.14--18.30, *P*=0.032, *z*=2.15) but not for cervical lymph nodes (OR =1.23, 95% CI =0.65--2.36, *P*=0.532, *z*=0.64).

Survival profile
----------------

Survival analyses showed that 1-year survival rate of taxane-containing IC regimens did not significantly differ from that of non-taxane-containing IC regimens (98.5% versus 96.2%; OR =1.19, 95% CI =0.10--14.82, *P*=0.893, *z*=0.13).

Hematological adverse events
----------------------------

The incidences of adverse events are summarized in [Table 3](#t3-ott-8-3255){ref-type="table"}. The occurrence rates of grade 3 and higher leukopenia were 46.7% and 22.4%, and those of grade 3--4 neutropenia were 39.1% and 16.1% in testing group and control group, respectively. As shown in [Figures 2](#f2-ott-8-3255){ref-type="fig"} and [3](#f3-ott-8-3255){ref-type="fig"}, patients treated with taxane-containing IC regimens in combination with CCRT had a significantly high incidence of grade 3--4 leukopenia (OR =3.21, 95% CI =2.14--4.83, *P*\<0.001, *z*=5.63) -- and neutropenia (OR =3.62, 95% CI =2.42--5.40, *P*\<0.001, *z*=6.29) compared to those treated with non-taxane-containing IC regimens. Meanwhile, there were no significant differences in the occurrence rate of other hematological adverse events, such as anemia (OR =1.46, 95% CI =0.81--2.63, *P*=0.214, *z*=1.24) and thrombocytopenia (OR =1.67, 95% CI =0.99--2.83, *P*=0.055, *z*=0.92) between these two groups.

Non-hematological adverse events
--------------------------------

Grade 3--4 vomiting (OR =0.67, 95% CI =0.45--0.99, *P*=0.043, *z*=2.03) was observed significantly different between the two groups in favor of the taxane-containing group ([Figure 4](#f4-ott-8-3255){ref-type="fig"}). There were similar incidences of other non-hematological toxicities between the two groups of patients receiving CCRT with or without the taxane-containing IC regimen, such as alanine aminotransferase elevation (OR =1.45, 95% CI =0.70--2.98, *P*=0.315, *z*=0.78), oral mucositis (OR =1.27, 95% CI =0.89--1.82, *P*=0.182, *z*=0.74), dermatitis (OR =0.98, 95% CI =0.49--1.99, *P*=0.963, *z*=0.05), and dry mouth (OR =0.96, 95% CI =0.33--2.81, *P*=0.941, *z*=0.09).

Risk of bias assessment
-----------------------

Data on the incidence of vomiting indicated a lack of heterogeneity across studies (*P*=0.013); thus, the random-effects model was used. The fixed-effects model was used in the incidence of other adverse events, short-term efficacy, and 1-year OS.

Discussion
==========

This study is the first RCT-based meta-analysis that evaluated clinical efficacy and safety of taxane-containing versus non-taxane-containing IC regimens in combination with CCRT regimen for locally advanced NPC in Chinese people, revealing remarkably improved ORR for nasopharyngeal lesion. In addition, the two IC regimens were well tolerated by all patients, although grade 3--4 vomiting was observed to be significantly different between the two groups in favor of the taxane-containing regimen, and grade 3--4 leukopenia and neutropenia were significantly different in favor of the non-taxane-containing regimen.

A few studies have focused on the taxane-containing IC regimen in combination with CCRT for NPC. In 2009, Hui et al[@b30-ott-8-3255] reported a Phase II trial of 60 patients with NPC (stage III--IVB), who were randomly assigned to receive CCRT alone or IC (docetaxel and cisplatin) subsequently in combination with CCRT, and observed a significantly improved 3-year OS for the latter with a manageable toxicity profile compared with CCRT alone. Bossi et al[@b31-ott-8-3255] reported a single-center study evaluating clinical efficacy and safety of IC regimen (docetaxel, cisplatin, and 5-fluorouracil) in combination with CCRT for Epstein--Barr virus-related locally advanced NPC, and revealed tolerated toxicity of the IC regimen of interest. These studies suggested that docetaxel is the major cancer drug in the taxane-containing IC regimens for advanced NPC, which is more efficient and well tolerated in patient care, consistent with the findings of our meta-analysis.

Some argument concerns that different IC and CCRT regimens and drugs utilized in each research might influence the comparison of the functions of taxane. In our meta-analysis, the conclusion of each independent research is obtained when expelling other factors which can interfere with the observation. Each independent research is focused on addressing the magnitude of the benefit and safety of taxane-containing regimen in advanced NPC treatment in Chinese population, which has been expelling other influencing factors.

In addition, of the hematologically adverse events, the incidence of grade 3--4 leukopenia and neutropenia was remarkably different between the two groups in favor of non-taxane-containing regimen, which is consistent with previous studies.[@b32-ott-8-3255],[@b33-ott-8-3255] But it was reported that neutropenia caused by taxane combined with cisplatin IC regimen would rebound quickly after using granulocyte colony-stimulating factor processing, while neutropenia caused by cisplatin combined with fluorouracil regimen recovered slower, leading to extended or interrupted treatment, although the rate of hematological toxicities was lower.[@b34-ott-8-3255] A number of clinical research studies have demonstrated that much higher proportion of NPC patients could complete all the chemotherapy,[@b15-ott-8-3255] or much more courses of chemotherapy could be completed[@b18-ott-8-3255],[@b21-ott-8-3255],[@b22-ott-8-3255] when patients received taxane-containing IC regimens than non-taxane-containing IC regimens, indicating that a higher completion rate of the taxane-containing IC regimens may be due to good tolerance.

Our meta-analysis indicated that the taxane-containing regimen has a significantly improved ORR for nasopharyngeal lesion but that its other short-term efficacy and survival profiles are similar to those of non-taxane-containing IC regimens. This is mainly because of the limitations to this meta-analysis. First of all, these RCTs included different taxane-containing IC regimens using two types of different taxanes: docetaxel or paclitaxel. However, the benefits and side effects of taxane-containing regimen do not seem to vary by the taxane. Second, two different types of CCRT regimens are used during radiation in these trials: taxane and cisplatin. Third, since the IC is used for a short period of time in NPC, the included trials have a short follow-up with no data on the relapse. Thus, we could only compare the short-term efficacy and 1-year survival profile between the two groups for NPC treatment. Last but most importantly, all NPC patients included in this meta-analysis are Chinese people, and the sample size is not large enough. The conclusions we have made cannot be extrapolated to NPC patients of other ethnic backgrounds.

Conclusion
==========

Limited RCTs have showed that taxane belongs to a class of clinically efficient antitumor drugs for locally advanced NPC, and that the taxane-containing IC regimen is superior to the non-taxane-containing regimen as assessed by a higher ORR in the former for primary nasopharyngeal lesions. In the future, more multicenter, large-scaled, high-quality RCTs are required to replicate and even confirm these findings in Chinese or other ethnic populations.
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###### 

Clinical characteristics of patients with nasopharyngeal carcinoma

  Study                          Published year   Sample size (n)   Median age (years)                             Inclusion period               Therapy regimen
  ------------------------------ ---------------- ----------------- ---------------------------------------------- ------------------------------ ----------------------------
  Li et al[@b14-ott-8-3255]      2012             35                46[a](#tfn1-ott-8-3255){ref-type="table-fn"}   September 2009--March 2011     IC (TPF) + CCRT (ddp + RT)
                                                  35                                                                                              IC (PF) + CCRT (ddp + RT)
  Lu et al[@b15-ott-8-3255]      2010             29                46                                             November 2005--November 2008   IC (TC) + CCRT (C + RT)
                                                  29                43                                                                            IC (FC) + CCRT (C + RT)
  Han et al[@b16-ott-8-3255]     2013             70                42                                             January 2005--December 2009    IC (TP) + CCRT (TP + RT)
                                                  76                45.6                                                                          IC (NP) + CCRT (NP + RT)
  Liu et al[@b17-ott-8-3255]     2013             31                45[a](#tfn1-ott-8-3255){ref-type="table-fn"}   August 2010--February 2012     IC (TPF) + CCRT (ddp + RT)
                                                  32                                                                                              IC (PF) + CCRT (ddp + RT)
  Xie et al[@b18-ott-8-3255]     2007             20                45                                             October 2005--March 2006       IC (TP) + CCRT (TP + RT)
                                                  20                44                                             March 2004--September 2005     IC (PF) + CCRT (PF + RT)
  Shi et al[@b19-ott-8-3255]     2013             30                44                                             January 2009--December 2010    IC (TP) + CCRT (ddp + RT)
                                                  30                46                                                                            IC (PF) + CCRT (ddp + RT)
  Ma et al[@b20-ott-8-3255]      2011             21                45[a](#tfn1-ott-8-3255){ref-type="table-fn"}   December 2009--March 2011      IC (TPF) + CCRT (ddp + RT)
                                                  24                                                                                              IC (PF) + CCRT (ddp + RT)
  Luo et al[@b21-ott-8-3255]     2011             32                52                                             March 2006--February 2009      IC (DN) + CCRT (N + RT)
                                                  32                54                                                                            IC (PF) + CCRT (N + RT)
  Wu et al[@b22-ott-8-3255]      2013             32                45[a](#tfn1-ott-8-3255){ref-type="table-fn"}   January 2010--December 2010    IC (DN) + CCRT (N + RT)
                                                  30                                                                                              IC (PF) + CCRT (N + RT)
  Huang et al[@b23-ott-8-3255]   2013             40                45[a](#tfn1-ott-8-3255){ref-type="table-fn"}   January 2010--June 2010        IC (TP) + CCRT (ddp + RT)
                                                  40                                                                                              IC (PF) + CCRT (ddp + RT)
  Ma et al[@b24-ott-8-3255]      2009             49                48[a](#tfn1-ott-8-3255){ref-type="table-fn"}   May 2003--August 2006          IC (TPF) + CCRT (PF + RT)
                                                  49                                                                                              IC (PF) + CCRT (PF + RT)
  Wu et al[@b25-ott-8-3255]      2014             23                44                                             N/A                            IC (TPF) + CCRT (ddp + RT)
                                                  26                43                                                                            IC (PF) + CCRT (ddp + RT)

**Notes:**

Only the average of all patients was provided. N/A, information was not available.

**Abbreviations:** IC, induction chemotherapy; TPF, docetaxel + cisplatin + 5-fluorouracil; CCRT, concurrent chemoradiotherapy; ddp, cisplatin; RT, radiotherapy; PF, cisplatin + 5-fluorouracil; TC, docetaxel + carboplatin; FC, carboplatin + 5-fluorouracil; TP, docetaxel + cisplatin; NP, vinorelbine + cisplatin; DN, docetaxel + nedaplatin; C, carboplatin; N, nedaplatin.

###### 

The short-term efficacy in two groups of the included studies

  Study                          Sample size   CR1   PR1   CR2   PR2
  ------------------------------ ------------- ----- ----- ----- -----
  Li et al[@b14-ott-8-3255]      35            31    4     N/A   N/A
                                 35            22    12    N/A   N/A
  Lu et al[@b15-ott-8-3255]      29            28    1     24    1
                                 29            28    1     21    2
  Han et al[@b16-ott-8-3255]     70            64    6     60    5
                                 76            72    4     65    6
  Liu et al[@b17-ott-8-3255]     31            26    5     N/A   N/A
                                 32            23    9     N/A   N/A
  Xie et al[@b18-ott-8-3255]     20            20    0     19    1
                                 20            18    2     15    3
  Shi et al[@b19-ott-8-3255]     30            25    5     N/A   N/A
                                 30            19    9     N/A   N/A
  Ma et al[@b20-ott-8-3255]      21            18    3     N/A   N/A
                                 24            13    10    N/A   N/A
  Luo et al[@b21-ott-8-3255]     32            31    1     26    2
                                 32            30    2     25    1
  Wu et al[@b22-ott-8-3255]      32            29    3     28    4
                                 30            26    4     25    5
  Huang et al[@b23-ott-8-3255]   40            38    2     36    4
                                 40            36    3     37    3
  Ma et al[@b24-ott-8-3255]      49            48    1     37    6
                                 49            45    4     36    8
  Wu et al[@b25-ott-8-3255]      23            19    3     N/A   N/A
                                 26            18    4     N/A   N/A

**Notes:** Data are expressed as n. N/A, information was not available.

**Abbreviations:** CR1, complete remission of primary nasopharyngeal lesion; PR1, partial release of primary nasopharyngeal lesion; CR2, complete remission of cervical lymph nodes; PR2, partial release of cervical lymph nodes.

###### 

The incidences of adverse events of the included studies

  Study                          Sample size   Leukopenia   Neutropenia   Anemia   Thrombocytopenia   ALT elevation   Vomiting   Oral mucositis   Dermatitis   Dry mouth
  ------------------------------ ------------- ------------ ------------- -------- ------------------ --------------- ---------- ---------------- ------------ -----------
  Li et al[@b14-ott-8-3255]      35            N/A          12            3        0                  N/A             4          26               0            0
                                 35            N/A          6             2        0                  N/A             3          22               0            0
  Lu et al[@b15-ott-8-3255]      29            16           21            5        0                  1               3          N/A              N/A          N/A
                                 29            6            11            6        2                  0               10         N/A              N/A          N/A
  Han et al[@b16-ott-8-3255]     70            N/A          30            8        8                  6               10         25               8            N/A
                                 76            N/A          16            4        5                  5               8          14               10           N/A
  Liu et al[@b17-ott-8-3255]     31            N/A          6             5        8                  4               N/A        9                N/A          2
                                 32            N/A          2             4        6                  3               N/A        11               N/A          3
  Xie et al[@b18-ott-8-3255]     20            16           N/A           0        0                  N/A             N/A        16               N/A          N/A
                                 20            2            N/A           9        2                  N/A             N/A        11               N/A          N/A
  Shi et al[@b19-ott-8-3255]     30            N/A          12            N/A      7                  N/A             11         N/A              N/A          N/A
                                 30            N/A          4             N/A      3                  N/A             19         N/A              N/A          N/A
  Ma et al[@b20-ott-8-3255]      21            6            N/A           2        1                  N/A             3          6                N/A          3
                                 24            4            N/A           1        0                  N/A             2          5                N/A          4
  Luo et al[@b21-ott-8-3255]     32            14           12            4        2                  N/A             0          0                0            N/A
                                 32            6            2             3        1                  N/A             5          1                0            N/A
  Wu et al[@b22-ott-8-3255]      32            14           10            3        3                  3               0          2                N/A          N/A
                                 30            6            3             2        2                  4               8          4                N/A          N/A
  Huang et al[@b23-ott-8-3255]   40            15           13            7        10                 3               6          3                N/A          N/A
                                 40            4            5             3        6                  1               9          11               N/A          N/A
  Ma et al[@b24-ott-8-3255]      49            29           N/A           N/A      N/A                N/A             17         18               10           N/A
                                 49            27           N/A           N/A      N/A                N/A             13         14               9            N/A
  Wu et al[@b25-ott-8-3255]      23            4            N/A           3        2                  N/A             2          2                N/A          2
                                 26            1            N/A           0        1                  N/A             1          2                N/A          1

**Notes:** Data are expressed as number of patients who suffered from a certain adverse event. N/A, information was not available.

**Abbreviation:** ALT, alanine aminotransferase.
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